BLOPEPBOLANG BIOTECHNOLOGY

Peptide Monographs

Retatrutide

An investigational peptide with agonist activity at GIPR, GLP-1R and GCGR. Use the linked publications and trial records to check study dates, populations, endpoints and development status.

Editorial educational content. Specialist review is not claimed; consult the original references and limitations.

Research overview

An investigational peptide with agonist activity at GIPR, GLP-1R and GCGR. Use the linked publications and trial records to check study dates, populations, endpoints and development status.

Identity and nomenclature

Check the sequence, termini, salt form and modifications for Retatrutide. Similar commercial names do not establish chemical equivalence.

Reading the evidence

For each reference, identify the experimental model, controls, endpoints and material tested. Cellular findings, animal findings and human trials answer different questions; a literature association does not establish use of a BLOPEP batch.

Analytical and storage documents

Use the product specification and batch certificate to check identity, purity and content. Follow material-specific storage information; no universal stability period is inferred from the peptide name.

Sources and verification scope

Inherited bibliography · catalog-retatrutide-phase2

Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial ↗

The New England Journal of Medicine / PubMed

Source details (original language)
Scope
Existing catalog reference associated with Retatrutide
Document section
PMID 37366315
Limitations
Inherited bibliographic record; not re-verified in this editorial migration. Follow the primary source. No product/batch-use claim.
Claim verification date
Inherited catalog reference; not re-verified in this migration
Inherited bibliography · catalog-retatrutide-triumph8

TRIUMPH-8: Retatrutide in participants with obesity or overweight ↗

ClinicalTrials.gov

Source details (original language)
Scope
Existing catalog reference associated with Retatrutide
Document section
NCT07232719
Limitations
Inherited bibliographic record; not re-verified in this editorial migration. Follow the primary source. No product/batch-use claim.
Claim verification date
Inherited catalog reference; not re-verified in this migration
Official / regulatory source · Q02

Q2(R2) Validation of Analytical Procedures ↗

FDA / ICH

Source details (original language)
Scope
Validation framework for analytical procedures
Document section
Final guidance summary
Limitations
Method validation does not certify this company or establish a result for a catalog lot.
Claim verification date
2026-09-09

Related commercial identities

Related research concerns the compound; it does not establish use of our product or lot in the study.

retatrutide →

Related reading